Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares (GlobeNewswire) - Feb 13, 2025 - "Oculis Holding AG...announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the 'Offering')....Oculis intends to use the net proceeds from the Offering to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes."
Commercial • CNS Disorders
|